Helicon Health CEO – Spotlight on Digital Therapeutics – Royal Society of Medicine – Wed. 18th January 2023
Digital Therapeutics (DTx) have been evolving for over a decade and promise to supplement or potentially replace some clinical therapies. Their potential value in facilitating significant benefits, such as meeting unmet patient needs, self-management and shared care of chronic conditions by patients, delivering treatment more affordably, reducing demands on clinician’s time or being a non-pharmacological treatment.
Join Helicon CEO, Tony Bowden and a number of clinical and industry luminaries at this in- person event that will provide an up-to date understanding of digital therapeutics and their role in conjunction with digital diagnostics.
Press Release: Download (PDF, 107 KB)